Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Noven Therapeutics
This is 12-week, multicenter, double-blind, randomized, placebo-controlled study of Brisdelle (paroxetine mesylate) Capsules 7.5 mg and placebo capsules in subjects with moderate to severe postmenopausal VMS, defined as follows:
* Moderate VMS: Sensation of heat with sweating, able to continue activity
* Severe VMS: Sensation of heat with sweating, causing cessation of activity
The study is comprised of a screening period, a run-in period, a baseline visit, and a double-blind treatment period.
Age
40–any
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
1. Female, ≥ 40 years of age at screening (inclusive)
2. Reported more than 7-8 moderate to severe hot flashes per day (average) or 50-60 moderate to severe hot flashes per week for at least 30 days prior to the screening visit
3. Spontaneous amenorrhea for at least 12 consecutive months or
4. Amenorrhea for at least 6 months and meet the biochemical criteria for menopause or
5. Bilateral salpingo-oophorectomy ≥ 6 weeks with or without hysterectomy
You may not be if
1. Known non-responder to previous Selective serotonin reuptake inhibitor (SSRI) or Serotonin norepinephrine reuptake inhibitor (SNRI) treatment for VMS
2. History of self injurious behavior
3. History of clinical diagnosis of depression or treatment for depression
4. History of clinical diagnosis of borderline personality disorder
5. Use of an investigational study medication within 30 days prior to screening or during the study
6. Concurrent participation in another clinical trial or previous participation in this trial